Phase 1 Study of the Administration of Ipilimumab Intra-Lymphatically Using the Sofusa DoseConnect DEVICE With Nivolumab Administered IV in Patients With Metastatic Melanoma
Latest Information Update: 12 Dec 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mayo Clinic
- 10 Dec 2024 Status changed from active, no longer recruiting to discontinued.
- 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2023 Planned End Date changed from 30 Jul 2024 to 1 Jul 2025.